EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis

Published:2020-07 Issue: Volume:34 Page:101571
ISSN:2213-2317
Container-title:Redox Biology
language:en
Short-container-title:Redox Biology

Author:

Fan Chi-Chen,Tsai Sheng-Ta,Lin Chen-Yuan,Chang Ling-Chu,Yang Juan-Cheng,Chen Guan‐Yu,Sher Yuh-Pyng,Wang Shao-Chun,Hsiao Michael,Chang Wei‐Chao

Funder

Ministry of Science and Technology, Taiwan

China Medical University Hospital

Publisher

Elsevier BV

Subject

Organic Chemistry,Biochemistry,Clinical Biochemistry

Reference59 articles.

1. Cancer statistics, 2017;Siegel;Ca - Cancer J. Clin.,2017

2. Non-small-cell lung cancer;Goldstraw;Lancet,2011

3. American College of Chest Physicians, Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition);Scott;Chest,2007

4. Comparing treatment strategies for stage I small-cell lung cancer;Paximadis;Clin. Lung Canc.,2018

5. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data;Lancet,2014

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting EFHD2 inhibits interferon-γ signaling and ameliorates non-alcoholic steatohepatitis;Journal of Hepatology;2024-09

2. Aqueous Extracts of Ocimum gratissimum Sensitize Hepatocellular Carcinoma Cells to Cisplatin through BRCA1 Inhibition;International Journal of Molecular Sciences;2024-08-01

3. Single cell transcriptomic analysis reveals tumor immune infiltration by NK cells gene signature in lung adenocarcinoma;Heliyon;2024-07

4. Novel pyxinol amide derivatives bearing an aliphatic heterocycle as P-glycoprotein modulators for overcoming multidrug resistance;European Journal of Medicinal Chemistry;2024-06

5. A novel Senescence-Based prognostic model unveils tumor interactions and drug resistance in colorectal cancer;International Immunopharmacology;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3